Payment overview · 2025
General Payments
$549.38
16 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph James Fallon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · STRATFORD, NJ · NPI 1760429369
Verified facts
What the public records show
CMS Open Payments records show Joseph James Fallon, M.D. received $549.38 in general payments during 2025 across 16 reported records.
Medtronic, Inc. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Rybelsus, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 1264 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 407 claims for Unithroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 571 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$267.92 | 48.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $127.46 | 23.2% | 6 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $55.23 | 10.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.32 | 6.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.45 | 3.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.51 | 3.0% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $16.17 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.32 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.46 | 15 |
| Travel and Lodging | $267.92 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $267.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $127.46 | 6 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $55.23 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 571 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 97 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 407 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
1264 | 339 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
407 | 138 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
571 | 115 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1711 | 475 |
| Synthroid | Levothyroxine Sodium | 1264 | 339 |
| Atorvastatin Calcium | Atorvastatin Calcium | 924 | 280 |
| Glimepiride | Glimepiride | 892 | 244 |
| Metformin Hcl | Metformin Hcl | 846 | 229 |
| Ezetimibe | Ezetimibe | 590 | 179 |
| Ozempic | Semaglutide | 571 | 115 |
| Pioglitazone Hcl | Pioglitazone Hcl | 480 | 125 |
| Jardiance | Empagliflozin | 421 | 93 |
| Unithroid | Levothyroxine Sodium | 407 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 91 |
| Farxiga | Dapagliflozin Propanediol | 278 | 70 |
| Trulicity | Dulaglutide | 269 | 66 |
| Calcitriol | Calcitriol | 256 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 232 | 88 |
| Vascepa | Icosapent Ethyl | 228 | 57 |
| Chlorthalidone | Chlorthalidone | 224 | 67 |
| Spironolactone | Spironolactone | 187 | 59 |
| Levoxyl | Levothyroxine Sodium | 173 | 48 |
| Repaglinide | Repaglinide | 167 | 51 |
| Mounjaro | Tirzepatide | 161 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 156 | 61 |
| Liothyronine Sodium | Liothyronine Sodium | 153 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 57 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 147 | 50 |
| Ramipril | Ramipril | 142 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 36 |
| Glipizide Er | Glipizide | 133 | 34 |
| Tresiba Flextouch U-100 | Insulin Degludec | 130 | 42 |
| Indapamide | Indapamide | 125 | 39 |
| Losartan Potassium | Losartan Potassium | 124 | 41 |
| Famotidine | Famotidine | 118 | 38 |
| Lisinopril | Lisinopril | 115 | 32 |
| Irbesartan | Irbesartan | 111 | 38 |
| Januvia | Sitagliptin Phosphate | 110 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 28 |
| Rybelsus | Semaglutide | 97 | 27 |
| Humalog Kwikpen U-100 | Insulin Lispro | 96 | 35 |
| Invokana | Canagliflozin | 93 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 33 |
| Novolog Flexpen | Insulin Aspart | 91 | 28 |
| Tradjenta | Linagliptin | 90 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 86 | 28 |
| Furosemide | Furosemide | 84 | 28 |
| Alendronate Sodium | Alendronate Sodium | 83 | 26 |
| Metformin Hcl Er | Metformin Hcl | 80 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 28 |
| Omeprazole | Omeprazole | 74 | 29 |
| Simvastatin | Simvastatin | 71 | 22 |
| Alprazolam | Alprazolam | 70 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 70 | 27 |
| Allopurinol | Allopurinol | 69 | 17 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 69 | 40 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 67 | 22 |
| Gabapentin | Gabapentin | 67 | 19 |
| Methimazole | Methimazole | 64 | 17 |
| Testosterone | Testosterone | 64 | 11 |
| Lorazepam | Lorazepam | 61 | 24 |
| Hydrocortisone | Hydrocortisone | 60 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | 21 |
| Risedronate Sodium | Risedronate Sodium | 58 | 24 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 57 | 19 |
| Potassium Chloride | Potassium Chloride | 57 | 18 |
| Amiloride Hcl | Amiloride Hcl | 56 | 15 |
| Kerendia | Finerenone | 56 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | 21 |
| Atenolol | Atenolol | 52 | 16 |
| Humalog | Insulin Lispro | 52 | 11 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Glyburide | Glyburide | 49 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 49 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 40 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 39 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 36 | 11 |
| Tirosint | Levothyroxine Sodium | 36 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | 14 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 33 | suppressed |
| Novolog | Insulin Aspart | 33 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | 12 |
| Xyosted | Testosterone Enanthate | 29 | suppressed |
| Cabergoline | Cabergoline | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Nexletol | Bempedoic Acid | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Niacin Er | Niacin | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Miglitol | Miglitol | 13 | suppressed |
| Cefadroxil | Cefadroxil | 12 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Droplet Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.38 · 16 records | Medtronic, Inc. | GVOKE HYPOPEN, Kerendia, MINIMED 780G, Ozempic, Rybelsus, UNITHROID, Yorvipath | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error